Immunotherapy for advanced melanoma: future directions.
| dc.contributor.author | Valpione, Sara | |
| dc.contributor.author | Campana, L | |
| dc.date.accessioned | 2016-02-18T15:06:48Z | en |
| dc.date.available | 2016-02-18T15:06:48Z | en |
| dc.date.issued | 2016-02 | en |
| dc.identifier.citation | Immunotherapy for advanced melanoma: future directions. 2016, 8 (2):199-209 Immunotherapy | en |
| dc.identifier.issn | 1750-7448 | en |
| dc.identifier.pmid | 26809078 | en |
| dc.identifier.doi | 10.2217/imt.15.111 | en |
| dc.identifier.uri | http://hdl.handle.net/10541/596625 | en |
| dc.description.abstract | As calculated by the meta-analysis of Korn et al., the prognosis of metastatic melanoma in the pretarget and immunological therapy era was poor, with a median survival of 6.2 and a 1-year life expectancy of 25.5%. Nowadays, significant advances in melanoma treatment have been gained, and immunotherapy is one of the promising approaches to get to durable responses and survival improvement. The aim of the present review is to highlight the recent innovations in melanoma immunotherapy and to propose a critical perspective of the future directions of this enthralling oncology subspecialty. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Immunotherapy | en |
| dc.title | Immunotherapy for advanced melanoma: future directions. | en |
| dc.type | Article | en |
| dc.contributor.department | Christie Hospital NHS Foundation Trust, 550 Wilmslow Rd, Manchester, M20 4BX | en |
| dc.identifier.journal | Immunotherapy | en |
| html.description.abstract | As calculated by the meta-analysis of Korn et al., the prognosis of metastatic melanoma in the pretarget and immunological therapy era was poor, with a median survival of 6.2 and a 1-year life expectancy of 25.5%. Nowadays, significant advances in melanoma treatment have been gained, and immunotherapy is one of the promising approaches to get to durable responses and survival improvement. The aim of the present review is to highlight the recent innovations in melanoma immunotherapy and to propose a critical perspective of the future directions of this enthralling oncology subspecialty. |